1005 related articles for article (PubMed ID: 12492193)
1. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
3. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
5. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
Kam L; Cohen H; Dooley C; Rubin P; Orchard J
Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
[TBL] [Abstract][Full Text] [Related]
6. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
7. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
8. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
[TBL] [Abstract][Full Text] [Related]
9. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
10. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
11. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
[TBL] [Abstract][Full Text] [Related]
13. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.
Safdi M; DeMicco M; Sninsky C; Banks P; Wruble L; Deren J; Koval G; Nichols T; Targan S; Fleishman C; Wiita B
Am J Gastroenterol; 1997 Oct; 92(10):1867-71. PubMed ID: 9382054
[TBL] [Abstract][Full Text] [Related]
14. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Muijsers RB; Goa KL
Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
[TBL] [Abstract][Full Text] [Related]
15. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
16. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
[TBL] [Abstract][Full Text] [Related]
18. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
[TBL] [Abstract][Full Text] [Related]
19. Review article: balsalazide therapy in ulcerative colitis.
Ragunath K; Williams JG
Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
